Abbott Laboratories Stock News

Harvey Investment Co. LLC reduced its holdings in Abbott Laboratories (NYSE:ABT) by 0.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 227,071 shares of the healthcare product maker’s stock after selling 375 shares during the quarter. Abbott Laboratories comprises about 3.5% of Harvey Investment Co. LLC’s investment portfolio, making the stock its 9th biggest […]

The recent research publication on Neuromodulation Devices Market: Current market provides insights about evolution of the competitive environment, the lifecycle stage and opportunities. The survey with Neuromodulation Devices Market: Current investors & stakeholders in this sector, from APAC, EMEA and

Ausdal Financial Partners Inc. cut its stake in Abbott Laboratories (NYSE:ABT) by 1.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,672 shares of the healthcare product makers stock after selling 80 shares during the period. Ausdal Financial Partners Inc.s []

Abbott Laboratories (NYSE:ABT) SVP Louis H. Morrone sold 9,988 shares of Abbott Laboratories stock in a transaction that occurred on Friday, December 17th. The shares were sold at an average price of $137.54, for a total transaction of $1,373,749.52. The sale was disclosed in a legal filing with the SEC, which is available through the []

The "Diabetes Drug Therapy Market" report provides a comprehensive industry analysis for the forecast period of 2028. It provides a market research summary of the Diabetes Drug Therapy market with all major industry trends, market dynamics, and competitive scenarios. The

Publishers Antacid Medications market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights

SG Americas Securities LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 22.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 166,300 shares of the healthcare product makers stock after selling 46,846 shares during the period. SG []

Abbott (ABT) closed at $135.27 in the latest trading session, marking a +0.21% move from the prior day.

Could these health care stocks be worth looking out for as the new year approaches?

President Joe Biden announced his administration's strategy for curbing the spread of the omicron variant of the coronavirus includes ordering 500 million at-home tests to ship free to Americans. What

CMI Research has released the latest version of its survey report on the Cardiac Implant Market, which includes 100+ market data tables, a pie chart, graphs and figures scattered over pages. The market is currently expanding its footprint. The research

Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.

ABT vs. RMD: Which Stock Is the Better Value Option?

Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.

ABBOTT PARK, Ill., Dec. 21, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P.